Company Profiles

driven by the PitchBook Platform

Alzheon

Description

Developer of drugs intended to make advances in the challenging field of therapeutics for Alzheimer's and other neurological disorders. The company's drug is a pill with a favorable safety profile and has the potential to modify an underlying cause of the Alzheimer's disease enabling patients to have improved life by improving their tolerability profile.

2013

Founded

PRIVATE

Status

11-50

Employees

Series B

Latest Deal Type

$15.8M

Latest Deal Amount

$27M

Total Amount Raised

Description

Developer of drugs intended to make advances in the challenging field of therapeutics for Alzheimer's and other neurological disorders. The company's drug is a pill with a favorable safety profile and has the potential to modify an underlying cause of the Alzheimer's disease enabling patients to have improved life by improving their tolerability profile.

Website:

www.alzheon.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

111 Speen Street Suite 306 Framingham, MA 01701United States +1 (508) 861-7709
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Alzheon's full profile, request a free trial.

Alzheon Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Alzheon Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Alzheon Investors (2)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Ally Bridge GroupVenture CapitalMinority000 0000000 0000
Individual InvestorAngel (individual)Minority000 0000000 0000
Ally Bridge Group Venture Capital
Individual Investor Angel (individual)

Alzheon Executive Team (6)

NameTitleBoard
Seat
Contact
Info
John Hey Ph.DChief Scientific Officer
Neil Flanzraich JDChief Business Officer
Martin Tolar Ph.DFounder, President, Chief Executive Officer & Board Member
Kenneth MaceVice President, Finance
Petr Kocis Ph.DVice President, Preclinical Development
John Hey Ph.D Chief Scientific Officer
Neil Flanzraich JD Chief Business Officer
Martin Tolar Ph.D Founder, President, Chief Executive Officer & Board Member
Kenneth Mace Vice President, Finance
Petr Kocis Ph.D Vice President, Preclinical Development

Alzheon Board Members (9)

NameRepresentingRoleSinceContact
Info
David Nikodem Ph.DAlly Bridge GroupManaging Director000 0000
Dennis Langer MDSelfBoard Member000 0000
Franklin BergerSelfAngel (individual)000 0000
Franz Hefti Ph.DSelfBoard Member000 0000
Jean-Pierre Garnier Ph.DSelfChairman000 0000
David Nikodem Ph.D Managing Director Ally Bridge Group
Dennis Langer MD Board Member Self
Franklin Berger Angel (individual) Self
Franz Hefti Ph.D Board Member Self
Jean-Pierre Garnier Ph.D Chairman Self
Request full access to PitchBook